HBM Holdings Ltd. stock analysis
Want to see HK:2142 full AI Analyst Report?
HBM Holdings Ltd. (2142) Stock Price & Analysis
2142 Stock Chart & Stats
- Day’s Range
- HKD 10.40 - HKD 10.94
- 52-Week Range
- HKD 9.28 - HKD 17.07
- Previous Close
- HKD 10.94
- Volume
- N/A
- Average Volume (3M)
- 8.60M
- Market Cap
- HKD 9.42B
- Enterprise Value
- HKD 6.74B
- Total Cash (Recent Filing)
- HKD 359.55M
- Total Debt (Recent Filing)
- HKD 89.70M
- Price to Earnings (P/E)
- 13.3
- Beta
- 1.36
- Next Earnings
- Mar 31, 2027 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
The sharp 2025 revenue increase indicates substantially stronger recent commercial performance and market activity. If the company can retain this scale of growth, it should improve operating leverage, support continued investment, and strengthen its ability to build a more durable earnings base.
Profitability Improvement
Very high 2025 gross and net margins show that the recent revenue expansion translated into substantial profitability rather than growth with weak economics. Such margins can support internal funding, resilience, and reinvestment, provided the improved performance remains sustainable over coming periods.
Cash Generation
Positive operating and free cash flow in 2025 demonstrates that reported earnings converted into usable liquidity, with free cash flow representing about 86% of net income. This improves the company’s capacity to fund operations and investment without relying as heavily on external financing.
Bears Say
Earnings Volatility
The strong 2025 rebound follows materially uneven results, including a 2024 revenue decline and substantial changes in profitability across years. This volatility reduces confidence that the latest growth and margins represent a stable operating trajectory, making medium-term earnings durability less certain.
History Of Losses
Heavy historical losses and deeply negative returns show that the company has previously struggled to generate dependable economic returns. Although 2025 improved sharply, the earlier record indicates that profitability and balance-sheet strength remain dependent on maintaining the recent operating recovery.
Cash Flow Instability
Prior periods of large cash burn and negative operating and free cash flow demonstrate that liquidity generation has not been consistent. This creates uncertainty around the company’s ability to fund reinvestment internally through weaker periods and increases the importance of sustaining recent cash conversion.
HBM Holdings Ltd. News
HBM Holdings Sets Commercial Path for Core Myasthenia Drug in Greater China
HBM Holdings Ltd. ( ($HK:2142) ) has shared an announcement. HBM Holdings Ltd., a Cayman-incorporated biopharmaceutical group listed in Hong Kong, is focused on antibody-based therapies for autoimmune and neurological
HBM Holdings Partner Solstice Oncology Secures US$225 Million Series A for Neoadjuvant Immunotherapy Push
HBM Holdings Ltd. ( ($HK:2142) ) has shared an announcement. HBM Holdings Ltd. reported that its partner Solstice Oncology has launched with a US$225 million Series A financing round led
HBM Holdings Clarifies Executive Director Resignation and Confirms Board Changes
HBM Holdings Ltd. ( ($HK:2142) ) has issued an update. HBM Holdings Limited has issued a supplemental announcement clarifying the circumstances surrounding a recent leadership reshuffle, including the resignation of
2142 FAQ
What was HBM Holdings Ltd.’s price range in the past 12 months?
What is HBM Holdings Ltd.’s market cap?
When is HBM Holdings Ltd.’s upcoming earnings report date?
How were HBM Holdings Ltd.’s earnings last quarter?
Is HBM Holdings Ltd. overvalued?
Does HBM Holdings Ltd. pay dividends?
What is HBM Holdings Ltd.’s EPS estimate?
How many shares outstanding does HBM Holdings Ltd. have?
What happened to HBM Holdings Ltd.’s price movement after its last earnings report?
Which hedge fund is a major shareholder of HBM Holdings Ltd.?
What is the TipRanks Smart Score and how is it calculated?
HBM Holdings Ltd. Stock Smart Score
Company Description
HBM Holdings Ltd.
HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused on identifying and developing unique antibody-based treatments for a variety of immunological conditions and cancers. The company's pipeline includes several promising assets. In immunology, Batoclimab (HBM9161) is a human monoclonal antibody specifically designed to bind and inhibit the neonatal fragment crystallizable receptor, while Tanfanercept (HBM9036) is under development to address moderate to severe dry eye disease. For oncology, HBM Holdings is advancing various therapies, such as HBM7008, a bispecific antibody targeting tumor-associated antigens, and HBM4003, a human anti-CTLA-4 antibody. Additional cancer candidates in their portfolio include HBM9302 for breast and gastric cancers, HBM7020 for multiple myeloma, and a suite of treatments—HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022—geared towards solid tumors. Furthermore, HBM9022 is being developed to treat SARS-COV-2. Operating globally, HBM Holdings has a presence in Mainland China, the United States, Europe, and other international markets. The company also fosters strategic partnerships for antibody-drug conjugate (ADC) projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was founded in 2016 and is based in Shanghai, People's Republic of China.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Jingsong Wang
- Employees
- 327
- Website
- www.harbourbiomed.com
- Address
- Building A3, Suzhou, SH, 215123, CN
HBM Holdings Ltd. (2142) Earnings & Revenues
2142 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 5 | 4 | 13 |
| Technical Analysis | 3 | 4 | 3 |
| Moving Averages | 2 | 0 | 10 |









